Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: guntupalli sr. Mol Cancer Res. 2024 Aug 13. doi: 10.1158/1541-7786.MCR-24-0067. Online ahead of print. Mol Cancer Res. 2024. PMID: 39136655
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: guntupalli sr. Mol Cancer Ther. 2024 Jun 12:OF1-OF16. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38863225
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: guntupalli sr. Mol Cancer Ther. 2024 May 8. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38714351
Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.
Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, Aisner DL, Wolsky RJ. Davies KD, et al. Among authors: guntupalli sr. Int J Gynecol Pathol. 2024 Jul 1;43(4):335-348. doi: 10.1097/PGP.0000000000000994. Epub 2023 Oct 4. Int J Gynecol Pathol. 2024. PMID: 37922951
Cancer and the risk of perioperative arterial ischaemic events.
Navi BB, Zhang C, Kaiser JH, Liao V, Cushman M, Kasner SE, Elkind MSV, Tagawa ST, Guntupalli SR, Gaudino MFL, Lee AYY, Khorana AA, Kamel H. Navi BB, et al. Among authors: guntupalli sr. Eur Heart J Qual Care Clin Outcomes. 2024 Jun 20;10(4):345-356. doi: 10.1093/ehjqcco/qcad057. Eur Heart J Qual Care Clin Outcomes. 2024. PMID: 37757472
Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: guntupalli sr. bioRxiv [Preprint]. 2023 Feb 23:2023.02.23.529773. doi: 10.1101/2023.02.23.529773. bioRxiv. 2023. PMID: 36865165 Free PMC article. Preprint.
70 results